keyword
MENU ▼
Read by QxMD icon Read
search

Breast chemotherapy adjuvant and primary

keyword
https://www.readbyqxmd.com/read/28098562/primary-neuroendocrine-carcinoma-of-the-breast-a-single-center-experience-and-review-of-the-literature
#1
Paolo Locurto, Angelo Danilo Antona, Antonietta Grillo, Antonio Ciulla, Stefania Martorana, Calogero Cipolla, Giuseppa Graceffa, Salvatore Vieni
: Neuroendocrine carcinoma of the breast is an extremely rare tumor. A standard treatment has yet to be established because only a few cases have been reported in literature. The authors report five cases observed from January 2007 to December 2014 and a review of literature. Four patients underwent quadrantectomy and in two cases axillary nodal dissection and only one to mastectomy with axillary nodal dissection. Tumor size was from T1 to T2 with N0 to N1, according TNM classification...
December 6, 2016: Annali Italiani di Chirurgia
https://www.readbyqxmd.com/read/28066861/the-incidence-of-cardiomyopathy-in-brca1-and-brca2-mutation-carriers-after-anthracycline-based-adjuvant-chemotherapy
#2
Edward J Pearson, Anju Nair, Yahya Daoud, Joanne L Blum
PURPOSE: Breast cancer remains the fourth-leading cause of death in the United States. Nearly 10% of breast cancers are hereditary, with deleterious mutations in BRCA1 and BRCA2 genes being the leading cause. Anthracycline chemotherapy, used commonly for breast cancer, carries cardiotoxicity risk. Recent studies demonstrated anthracycline-induced cardiac failure in homozygous BRCA2-deficient mice and increased rates of heart failure in homozygous BRCA1-deficient mice following ischemic insult...
January 9, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28053622/role-of-ovarian-function-suppression-in-premenopausal-women-with-early-breast-cancer
#3
REVIEW
Woo-Chan Park
Historically, endocrine therapy for breast cancer began with ovarian ablation (OA) for the treatment of premenopausal patients. After the identification of estrogen receptors and the development of many antiestrogens, tamoxifen has been approved and used as the standard endocrine therapy for hormonal receptor (HR)-positive premenopausal patients to date. With the development of luteinizing hormone-releasing hormone agonists, the paradigm of endocrine therapy for premenopausal women with HR-positive breast cancer began to change from OA to ovarian function suppression (OFS)...
December 2016: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28045625/ki67-proliferation-index-as-a-tool-for-chemotherapy-decisions-during-and-after-neoadjuvant-aromatase-inhibitor-treatment-of-breast-cancer-results-from-the-american-college-of-surgeons-oncology-group-z1031-trial-alliance
#4
Matthew J Ellis, Vera J Suman, Jeremy Hoog, Rodrigo Goncalves, Souzan Sanati, Chad J Creighton, Katherine DeSchryver, Erika Crouch, Amy Brink, Mark Watson, Jingqin Luo, Yu Tao, Michael Barnes, Mitchell Dowsett, G Thomas Budd, Eric Winer, Paula Silverman, Laura Esserman, Lisa Carey, Cynthia X Ma, Gary Unzeitig, Timothy Pluard, Pat Whitworth, Gildy Babiera, J Michael Guenther, Zoneddy Dayao, David Ota, Marilyn Leitch, John A Olson, D Craig Allred, Kelly Hunt
Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) -positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level was > 10% after 2 to 4 weeks of neoadjuvant aromatase inhibitor (AI) therapy. A second objective was to examine risk of relapse using the Ki67-based Preoperative Endocrine Prognostic Index (PEPI). Methods The American College of Surgeons Oncology Group (ACOSOG) Z1031A trial enrolled postmenopausal women with stage II or III ER-positive (Allred score, 6 to 8) breast cancer whose treatment was randomly assigned to neoadjuvant AI therapy with anastrozole, exemestane, or letrozole...
January 3, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28039893/chemotherapy-in-old-women-with-breast-cancer-is-age-still-a-predictor-for-under-treatment
#5
Mégane Meresse, Anne-Déborah Bouhnik, Marc-Karim Bendiane, Frédérique Retornaz, Frédérique Rousseau, Dominique Rey, Roch Giorgi
Breast cancer affects mostly older women but there are no guidelines especially devoted to adjuvant chemotherapy for this population. In this context, this study was carried out in a population-based cohort of French elderly women with breast cancer, to check adherence to the existing national guidelines according to the women's age, taking into account the evolution of the situation over time for women requiring chemotherapy. Between October 2006 and December 2008, all consecutive women included in the French Health registry for a biopsy-proven primary nonmetastatic breast cancer, aged 65-80 years at diagnosis, and living in South Eastern France, were asked to participate in a cohort study...
December 31, 2016: Breast Journal
https://www.readbyqxmd.com/read/28008267/oncological-outcomes-and-complications-after-volume-replacement-oncoplastic-breast-conservations-the-glasgow-experience
#6
Weiguang Ho, Sheila Stallard, Julie Doughty, Elizabeth Mallon, Laszlo Romics
INTRODUCTION: Oncoplastic breast conservation surgery (OBCS) combines the principles of surgical oncology and plastic surgery. OBCS has now become a growing option for the treatment of breast cancer and forms a part of breast-conserving therapy (BCT). We sought to investigate and report our experience in two breast units in Glasgow (Victoria Infirmary and Western Infirmary) on volume replacement OBCS. MATERIALS AND METHODS: Details of patients treated with volume replacement OBCS were identified from a prospectively recorded database from November 2010 to October 2015...
2016: Breast Cancer: Basic and Clinical Research
https://www.readbyqxmd.com/read/28006055/association-of-dna-mismatch-repair-and-mutations-in-braf-and-kras-with-survival-after-recurrence-in-stage-iii-colon-cancers-a-secondary-analysis-of-2-randomized-clinical-trials
#7
Frank A Sinicrope, Qian Shi, Carmen J Allegra, Thomas C Smyrk, Stephen N Thibodeau, Richard M Goldberg, Jeffrey P Meyers, Kay L Pogue-Geile, Greg Yothers, Daniel J Sargent, Steven R Alberts
Importance: The association of biomarkers with patient survival after recurrence (SAR) of cancer is poorly understood but may guide management and treatment. Objective: To determine the association of DNA mismatch repair (MMR) status and somatic mutation in the B-Raf proto-oncogene (c.1799T>A [V600E]; BRAFV600E) or exon 2 of the KRAS proto-oncogene (KRAS) in the primary tumor with SAR in patients with stage III colon carcinomas treated with adjuvant chemotherapy...
December 22, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27994483/clinical-effects-of-prior-trastuzumab-on-combination-eribulin-mesylate-plus-trastuzumab-as-first-line-treatment-for-human-epidermal-growth-factor-receptor-2-positive-locally-recurrent-or-metastatic-breast-cancer-results-from-a-phase-ii-single-arm-multicenter
#8
Shannon Puhalla, Sharon Wilks, Adam M Brufsky, Joyce O'Shaughnessy, Lee S Schwartzberg, Erhan Berrak, James Song, Linda Vahdat
Eribulin mesylate, a novel nontaxane microtubule dynamics inhibitor in the halichondrin class of antineoplastic drugs, is indicated for the treatment of patients with metastatic breast cancer who previously received ≥2 chemotherapy regimens in the metastatic setting. Primary data from a Phase II trial for the first-line combination of eribulin plus trastuzumab in human epidermal growth factor receptor 2 positive patients showed a 71% objective response rate and tolerability consistent with the known profile of these agents...
2016: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/27993816/final-efficacy-and-updated-safety-results-of-the-randomized-phase-iii-beatrice-trial-evaluating-adjuvant-bevacizumab-containing-therapy-in-triple-negative-early-breast-cancer
#9
R Bell, J Brown, M Parmar, M Toi, T Suter, G G Steger, X Pivot, J Mackey, C Jackisch, R Dent, P Hall, N Xu, L Morales, L Provencher, R Hegg, L Vanlemmens, A Kirsch, A Schneeweiss, N Masuda, F Overkamp, D Cameron
PURPOSE: To assess the long-term impact of adding bevacizumab to adjuvant chemotherapy for early triple-negative breast cancer (TNBC). METHODS: Patients eligible for the open-label randomized phase III BEATRICE trial had centrally confirmed triple-negative operable primary invasive breast cancer (pT1a-pT3). Investigators selected anthracycline- and/or taxane-based chemotherapy for each patient. After definitive surgery, patients were randomized 1:1 to receive ≥4 cycles of chemotherapy alone or with 1 year of bevacizumab (5 mg/kg/week equivalent)...
December 19, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27992550/do-patients-with-luminal-a-breast-cancer-profit-from-adjuvant-systemic-therapy-a-retrospective-multicenter-study
#10
Joachim Diessner, Manfred Wischnewsky, Maria Blettner, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Roland Stein, Tanja Stüber, Lukas Schwentner, Catharina Bartmann, Achim Wöckel
BACKGROUND: Luminal A breast cancers respond well to anti-hormonal therapy (HT), are associated with a generally favorable prognosis and constitute the majority of breast cancer subtypes. HT is the mainstay of treatment of these patients, accompanied by an acceptable profile of side effects, whereas the added benefit of chemotherapy (CHT), including anthracycline and taxane-based programs, is less clear-cut and has undergone a process of critical revision. METHODS: In the framework of the BRENDA collective, we analyzed the benefits of CHT compared to HT in 4570 luminal A patients (pts) with primary diagnosis between 2001 and 2008...
2016: PloS One
https://www.readbyqxmd.com/read/27941567/a-serous-peritoneal-cancer-revealing-itself-with-double-breast-cancer-metastases-in-2-different-periods
#11
Kemal Beksac, Cigdem Irkkan, Guldeniz Argun, Bahadir Cetin
A 72-year-old woman presented with a mass on the right axilla. This was thought to be an occult breast cancer case, and the patient was treated with modified radical mastectomy, followed by hormonotherapy. Two years later she presented with incarcerated umbilical hernia. Pathology revealed Sister Mary Joseph's nodule inside the hernia sac. Further evaluation revealed that the primary tumor was papillary serous carcinoma of the peritoneal surface. The patient received adjuvant chemotherapy. Two years later the metastatic tumor was located on the other breast...
December 9, 2016: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/27919974/a-phase-ii-study-of-adjuvant-chemotherapy-of-tegafur-uracil-for-patients-with-breast-cancer-with-her2-negative-pathologic-residual-invasive-disease-after-neoadjuvant-chemotherapy
#12
Satoru Tanaka, Mitsuhiko Iwamoto, Kosei Kimura, Yuko Takahashi, Hiyoya Fujioka, Nayuko Sato, Risa Terasawa, Kanako Kawaguchi, Ayana Ikari, Tomo Tominaga, Saki Maezawa, Nodoka Umezaki, Junna Matsuda, Kazuhisa Uchiyama
BACKGROUND: There is no consensus on the need for adjuvant chemotherapy for patients with pathological residual invasive breast cancer (non-pCR) after neoadjuvant chemotherapy (NAC). We evaluated the tolerability and safety of tegafur-uracil (UFT) as adjuvant chemotherapy for patients with human epidermal growth factor receptor 2-negative breast cancer that resulted in non-pCR after NAC. PATIENTS AND METHODS: We treated patients with 270 mg/m(2) UFT per day for 2 years after definitive surgery and radiotherapy, if necessary...
2016: Anticancer Research
https://www.readbyqxmd.com/read/27909824/usefulness-of-ctc-and-dtc-bm-detection-for-adjuvant-therapy-effects-and-prognosis-prediction-in-early-breast-carcinoma-results-of-8-11-years-of-follow-up-evaluation
#13
Hiroshi Takeyama, T Shimada, S Kinoshita, K Uchida
BACKGROUND: Circulating tumor cells (CTCs) reportedly have been detected in the peripheral blood of more than 50% of breast carcinoma cases with distant metastases. Moreover, the survival period is shorter for patients who had more than five CTCs after a single chemotherapy treatment. However, a few data show the relationships between CTCs and expressions of disseminated tumor cells in the bone marrow (DTCs-BM), including treatment effects and prognoses in early breast carcinomas. METHODS: In this study, CTCs and DTC-BMs were measured by the CellSearch System for 20 patients with stages 1-3 carcinomas, who were followed for 8-11 years...
December 1, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27905324/primary-neuroendocrine-carcinoma-of-the-breast-a-single-center-experience-and-review-of-the-literature
#14
Paolo Locurto, Angelo Danilo Antona, Antonietta Grillo, Antonio Ciulla, Stefania Martorana, Calogero Cipolla, Giuseppa Graceffa, Salvatore Vieni
: Neuroendocrine carcinoma of the breast is an extremely rare tumor. A standard treatment has yet to be established because only a few cases have been reported in literature. The authors report five cases observed from January 2007 to December 2014 and a review of literature. Four patients underwent quadrantectomy and in two cases axillary nodal dissection and only one to mastectomy with axillary nodal dissection. Tumor size was from T1 to T2 with N0 to N1, according TNM classification...
November 28, 2016: Annali Italiani di Chirurgia
https://www.readbyqxmd.com/read/27893634/comparison-of-different-acellular-dermal-matrix-adm-in-breast-reconstruction-the-50-50-study
#15
Troy A Pittman, Kenneth L Fan, Andrew Knapp, Shelby Frantz, Scott L Spear
BACKGROUND: Acellular Dermal Matrix (ADM) has enjoyed extensive use in primary and secondary alloplastic breast aesthetic and reconstructive surgery. The objective of this study is to examine clinical outcomes between available ADM: DermACELL(LifeNet Health, Virginia Beach, VA) and AlloDerm RTU (LifeCell, Branchburg, New Jersey). METHODS: A retrospective chart review was performed on 58 consecutive patients (100 breasts) reconstructed with either DermACELL(n=30 patients; 50 breasts) or AlloDerm RTU (n=28 patients; 50 breasts)...
November 21, 2016: Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/27892665/thyroid-function-after-postoperative-radiation-therapy-in-patients-with-breast-cancer
#16
Edyta Wolny-Rokicka, Andrzej Tukiendorf, Jerzy Wydmański, Danuta Roszkowska, Bogusław Staniul, Agnieszka Zembroń-Łacny
Objective: The aim of this study was to assess thyroid function in breast cancer patients exposed to therapeutic external beam radiation. The focus was on possible progressive changes and any relationships between the incidence of primary hypothyroidism, the time required to become hypothyroid, and factors such as chemotherapy, hormonotherapy and immunotherapy. Materials and Methods: Seventy females undergoing 3D conformal and IMRT radiation therapy for breast cancers were enrolled in a non-randomized prospective study...
1, 2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27853392/statins-and-risk-of-breast-cancer-recurrence
#17
Minas Sakellakis, Karolina Akinosoglou, Anastasia Kostaki, Despina Spyropoulou, Angelos Koutras
BACKGROUND: The primary end point of our study was to test whether the concurrent use of a statin is related to a lower risk of recurrence and increased relapse-free survival in patients with early breast cancer. MATERIALS AND METHODS: We reviewed 610 female patients with stage I, II, or III breast cancer who had been surgically treated and who had subsequently received at least adjuvant chemotherapy in order to prevent recurrence. RESULTS: Among the 610 patients with breast cancer, 83 (13...
2016: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/27852125/standardized-extract-from-caesalpinia-spinosa-is-cytotoxic-over-cancer-stem-cells-and-enhance-anticancer-activity-of-doxorubicin
#18
Tito A Sandoval, Claudia P Urueña, Mónica Llano, Alejandra Gómez-Cadena, John F Hernández, Luis Gonzalo Sequeda, Alix E Loaiza, Alfonso Barreto, Shaoping Li, Susana Fiorentino
Cancer stem cells (CSC) are the primary cell type responsible for metastasis and relapse. ABC-transporters are integral membrane proteins involved in the translocation of substrates across membranes protecting CSC from chemotherapeutic agents. A plant extract derived from C. spinosa (P2Et) previously investigated for its antitumor activity has been shown to reduce lung and spleen metastasis in mice that have been transplanted with breast cancer cells, suggesting that P2Et has a significant activity against cancer stem cells (CSC)...
2016: American Journal of Chinese Medicine
https://www.readbyqxmd.com/read/27842711/-radiation-related-heart-toxicity-update-in-women
#19
S Marlière, E Vautrin, C Saunier, A Chaikh, I Gabelle-Flandin
Breast cancer is a common diagnosis in women and thus women are at risk of radiation-induced heart disease, in particular during radiotherapy for left breast cancer and when the internal mammary chain is included. Rates of major cardiac events increase with younger age at the time of irradiation, diagnosis before 1990s, higher radiation doses, coexisting cardiovascular risk factors and adjuvant cardiotoxic chemotherapy. Radiation-induced heart disease comprises a spectrum of cardiac pathologies, including pericardial disease, cardiomyopathy, coronary artery disease and valvular disease...
December 2016: Annales de Cardiologie et D'angéiologie
https://www.readbyqxmd.com/read/27825007/effect-of-tailored-dose-dense-chemotherapy-vs-standard-3-weekly-adjuvant-chemotherapy-on-recurrence-free-survival-among-women-with-high-risk-early-breast-cancer-a-randomized-clinical-trial
#20
RANDOMIZED CONTROLLED TRIAL
Theodoros Foukakis, Gunter von Minckwitz, Nils-Olof Bengtsson, Yvonne Brandberg, Birgitta Wallberg, Tommy Fornander, Brigitte Mlineritsch, Sabine Schmatloch, Christian F Singer, Günther Steger, Daniel Egle, Eva Karlsson, Lena Carlsson, Sibylle Loibl, Michael Untch, Mats Hellström, Hemming Johansson, Harald Anderson, Per Malmström, Michael Gnant, Richard Greil, Volker Möbus, Jonas Bergh
Importance: Standard dosing of chemotherapy based on body surface area results in marked interpatient variation in pharmacokinetics, toxic effects, and efficacy. Whether tailored dosing can improve outcomes is unknown, as is the role of dose-dense adjuvant chemotherapy. Objective: To determine whether tailored dose-dense adjuvant chemotherapy improves the outcomes of early breast cancer compared with a standard 3-weekly chemotherapy schedule. Design, Setting, and Participants: A randomized, open-label, phase 3 trial of women aged 65 years and younger who had surgery for nonmetastatic node-positive or high-risk node-negative breast cancer at 86 sites in Sweden, Germany, and Austria between February 20, 2007, and September 14, 2011...
November 8, 2016: JAMA: the Journal of the American Medical Association
keyword
keyword
43929
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"